FindTrial
Sign In

We are doing a survey to understand how easy to use and satisfied women are with using the Pergoveris Prefilled Pen while undergoing fertility treatments (assisted reproductive technaology (ART), as part of their regular medical care.

A multicentre Patient satisfaction survey to evaluate the Pergoveris Pre-filled Pen supporting terms of ‘ease of use’ in women undergoing Assisted Reproductive Technology (ART) in accordance with routine clinical practice

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070849
Enrollment
150
Registered
2024-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Science of womanhood
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Women aged 18 years and above. 2. Willing and able to sign data disclosure consent form 3. Women undergoing assisted reproductive technology (ART) in accordance with routine clinical practice. 4. Women who have used Pergoveris® prefilled pen for consecutive 5 days

Exclusion criteria

Exclusion criteria: 1. Patients not willing to sign informed consent. 2. Less than 5 days consecutive use of the Pergoveris pen injection device

Design outcomes

Primary

MeasureTime frame
The primary endpoint: 1. Is the proportion of patients rating the Pen as “easy to use ? or “very easy to use ? for self-injection based on a patient User Survey 2. To evaluate overall satisfaction rating. Timepoint: 5 days—

Secondary

MeasureTime frame
Secondary Endpoint: The proportion of patients rating the Pergoveris Prefilled Pen for self injection in User Survey Questionnaires 1. Easy to use 2. Easy to learn Clarity and Understanding of the instructions for using the prefilled pen 3. Easy forself-administration 4. Minimize clinic visit and time 5. Overall convenience and portability of the device 6. Time saving due to device 7. Simplicity of its use 8. Overall opinion on using the injection deviceTimepoint: 5 days—

Countries

India

Contacts

Public ContactDr Rohit Gutgutia

Science of womanhood

drgutgutia@gmail.com9830017204

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026